Abstract:A nanoparticle (Combo‐NP) that contains biodegradable NIR‐II‐fluorescent pseudo conjugate polymer with disulfide bonds in the main chain (TPA‐BD) and a vascular inhibitor Lenvatinib (Len) is designed. Combo‐NP not only kill tumors by generating reactive oxygen species (ROS), but also trigger immunogenic cell death (ICD) initiating cascade immune responses leading to the production of cytotoxic T lymphocytes (CTLs). Moreover, Combo‐NP alleviate hypoxia by normalizing the tumor vessels, thereby improving the Photodynamic therapy (PDT)efficiency and increasing the infiltration of CTLs. These effects combine to amplify the photodynamic‐immunotherapy of the nanoparticles exhibiting promising inhibitory effects on tumor metastasis and inducing an abscopal immune response when combine with anti‐programmed death‐ligand 1 (PD‐L1) immunotherapy. Photodynamic therapy (PDT) has been widely employed in tumor treatment due to its effectiveness. However, the tumor hypoxic microenvironment which is caused by abnormal vasculature severely limits the efficacy of PDT. Furthermore, the abnormal vasculature has been implicated in the failure of immunotherapy. In this study, a novel nanoparticle denoted as Combo‐NP is introduced, composed of a biodegradable NIR II fluorescent pseudo‐conjugate polymer featuring disulfide bonds within its main chain, designated as TPA‐BD, and the vascular inhibitor Lenvatinib. Combo‐NP exhibits dual functionality by not only inducing cytotoxic reactive oxygen species (ROS) to directly eliminate tumor cells but also eliciting immunogenic cell death (ICD). This ICD response, in turn, initiates a robust cascade of immune reactions, thereby augmenting the generation of cytotoxic T lymphocytes (CTLs). In addition, Combo‐NP addresses the issue of tumor hypoxia by normalizing the tumor vasculature. This normalization process enhances the efficacy of PDT while concurrently fostering increased CTLs infiltration within the tumor microenvironment. These synergistic effects synergize to potentiate the photodynamic‐immunotherapeutic properties of the nanoparticles. Furthermore, when combined with anti‐programmed death‐ligand 1 (PD‐L1), they showcase notable inhibitory effects on tumor metastasis. The findings in this study introduce an innovative nanomedicine strategy aimed at triggering systemic anti‐tumor immune responses for the treatment of Uveal melanoma.

Nanoparticle-Based Combination Therapy for Melanoma

Multifunctional Nanoparticle Approach for Targeting Melanoma

Recent Progress in Nanomedicine for Melanoma Theranostics With Emphasis on Combination Therapy

Combinatorial Therapeutic Approaches with Nanomaterial-Based Photodynamic Cancer Therapy

Nano-mediated strategy: recent advance in the application of drug delivery systems in melanoma treatment and diagnosis

Exploiting in Situ Antigen Generation and Immune Modulation to Enhance Chemotherapy Response in Advanced Melanoma: A Combination Nanomedicine Approach.

Cancer nanomedicine: from targeted delivery to combination therapy

Combination Nanodrug Delivery Systems Facilitate the Syncretism of Chemotherapy with Immunotherapy to Promote Cancer Treatment

Melanoma treatment: from conventional to nanotechnology

Near‐Infrared‐II Nanoparticles for Vascular Normalization Combined with Immune Checkpoint Blockade via Photodynamic Immunotherapy Inhibit Uveal Melanoma Growth and Metastasis

Advances in the Application of Nanomaterials to the Treatment of Melanoma

Nanomedicine-enabled chemotherapy-based synergetic cancer treatments

Recent developments in nanomedicine for melanoma treatment

Recent Advances in Nanotechnology for the Treatment of Melanoma

Codelivery of afuresertib and celecoxib by IL4RPep-1-targeting nanoparticles for effective treatment against melanoma

Targeting Cancer using Polymeric Nanoparticle mediated Combination Chemotherapy

Cancer nanomedicine for combination cancer immunotherapy

Nanomedicine-Combined Immunotherapy for Cancer

Nano-immunotherapy: Unique mechanisms of nanomaterials in synergizing cancer immunotherapy

Effective Combinations of Immunotherapy and Radiotherapy for Cancer Treatment

Microneedle-Assisted Topical Delivery of Photodynamically Active Mesoporous Formulation for Combination Therapy of Deep-Seated Melanoma